04Feb/13

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia – The Pharma Letter

Roche’s obinutuzumab significantly improves PFS in chronic lymphocytic leukemia
The Pharma Letter
… with its investigational cancer drug obinutuzumab met its primary endpoint and an additional futility analysis suggested that it could show superiority compared to the company’s currently marketed MabThera/Rituxan (rituximab) in first line chronic …